Silence Therapeutics (LON:SLN) announced its quarterly earnings data on Tuesday, March 6th. The company reported GBX (2.30) (($0.03)) EPS for the quarter, Bloomberg Earnings reports. The firm had revenue of GBX 2 million for the quarter. Silence Therapeutics had a negative net margin of 34,475.00% and a negative return on equity of 21.42%.
Shares of Silence Therapeutics (LON SLN) traded up GBX 6 ($0.08) during midday trading on Wednesday, reaching GBX 202 ($2.79). 2,500 shares of the company’s stock were exchanged, compared to its average volume of 14,222. The company has a market cap of $137.24 and a P/E ratio of -10,100.00. Silence Therapeutics has a one year low of GBX 71.88 ($0.99) and a one year high of GBX 254.75 ($3.52).
Separately, Peel Hunt reiterated a “buy” rating and issued a GBX 275 ($3.80) price target on shares of Silence Therapeutics in a report on Monday, January 22nd.
COPYRIGHT VIOLATION WARNING: This piece was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2018/03/14/silence-therapeutics-sln-posts-earnings-results.html.
About Silence Therapeutics
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.